<?xml version="1.0" encoding="UTF-8"?>
<p>Evaluation of compounds for anti-proliferative activity against the breast cancer cell lines BT-474, MCF-10A, and MDA-MB-231 and pancreatic cell lines Bx-PC-3, Panc-1, and Su-86-86 was undertaken as described in detail by Lovitt et al. [
 <xref rid="B23-marinedrugs-19-00095" ref-type="bibr">23</xref>].
</p>
